Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.10.23

ICH-M7 Services

Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API

Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers' starting materials, intermediates, and final API for mutagenicity assessment.

As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities to limit the potential mutagenic risks to patients.

Sai’s ICH-M7 services include:

  • Comprehensive review of Routes Of Synthesis
  • Insilico assessment of compounds using Knowledge (Derek Nexus, Lhasa) and Statistical (TOPKAT, BIOVIA) approaches to assess genotoxicity and carcinogenicity alerts
  • Expert review and analysis to aid with decision making
  • Documentation of GTI assessment with justification (as per ICH-M7 classification)
  • In vitro and in vivo genotoxicity studies
  • Comprehensive review of all data, and recommendations for next steps
  • Support in identifying and implementing appropriate control strategies for mutagenic materials

Sai Life Sciences has handled over 100+ projects for its customers with their genotoxic impurity assessment and evaluation, helping them manage the risks associated with CMC regulatory concerns related to mutagenic risk.

To set up a meeting with our expert, email contact@sailife.com.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more